Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Regeneron Pharmaceuticals Inc (NASDAQ:REGN)

During the Trading Day
496.42 -17.08 / -3.33%
As of 3:59pm ET
Day’s Change
During After-Hours   Switch to standard view »
496.42 0.00 / 0.00%
Volume: 13.0K
Amicus (FOLD) Signs Agreement to Acquire Scioderm
6:26pm / Zacks.com
J&J to Sell Sugar Substitute Splenda to Heartland Food
Aug 26 / Zacks.com
Intercept's (ICPT) OCA Under Priority Review in the U.S.
6:26pm / Zacks.com
Sarepta's DMD Drug Eteplirsen Gains FDA Priority Review
Aug 26 / Zacks.com
Trevena's Postoperative Pain Drug Positive in Phase IIb Study
5:38pm / Zacks.com
Drugs Stocks On The Rise With Help From 3 Stocks
Aug 26 / TheStreet.com
4 Winning Stocks with the Potential to Beat the Market
11:53am / Zacks.com
Bouncing Biotech? 3 Stocks To Buy
Aug 25 / MotleyFool.com
Applied Genetic Meets Enrolment Milestone in XLRS Study
Aug 31 / Zacks.com
Seres (MCRB) Up on Orphan Drug Status for Lead Candidate
Aug 24 / Zacks.com
Pfizer (PFE) Gains on Label Expansion Efforts for Ibrance
Aug 28 / Zacks.com
Alkermes' (ALKS) Aristada Review Date Postponed by FDA
Aug 24 / Zacks.com
Exelixis Up on Swiss Approval of Advanced Melanoma Drug
Aug 28 / Zacks.com
Bull Or Bear? Biotech's Post-Earnings Buys and Sells
Aug 23 / MotleyFool.com
Amgen's PCSK9 Inhibitor, Repatha, Approved in the U.S.
Aug 28 / Zacks.com
Pfizer's (PFE) Breast Cancer Drug Ibrance Under EU Review
Aug 21 / Zacks.com
Time to Buy Amgen After Newly Approved Drug?
Aug 28 / TheStreet.com
Raptor (RPTP) to Buy Quinsair, Boost Rare Disease Portfolio
Aug 21 / Zacks.com
Oncolytics' Reolysin Phase II Lung Cancer Study Enrolled
Aug 27 / Zacks.com
Vascular (VBLT) Starts Patient Dosing in Glioblastoma Study
Aug 21 / Zacks.com
Regeneron Pharmaceuticals (REGN) Stock Is the 'Chart of the Day'
Aug 27 / TheStreet.com
Why Eli Lilly (LLY) was a Bright Spot in the Market on Thursday
Aug 21 / Zacks.com
Regeneron Shows a High Volume Bottom
Aug 27 / TheStreet.com
Google's 11-Year Dream Run: From IPO to Alphabet
Aug 20 / Zacks.com
How China's Troubles Affect Biotech and Pharma Stocks: Part 1
Aug 27 / TheStreet.com
This Is a Concern That Amgen Investors Shouldn't Take Lightly
Aug 20 / MotleyFool.com